Back

The risk of failure of subcutaneous implantable cardioverter defibrillator therapy: from PRAETORIAN score to clinical practice

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Device complications and lead extraction Device Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Matteo Ziacchi

IRCCS Sant'Orsola Polyclinic, Bologna (Italy)

6 More presentations in this session

Presentation thumbnail
Multicentric experience with the use of short 13Fr bidirectional mechanical rotating dilator sheath for transvenous lead extraction
Doctor A. Preda (Milan, IT)
Abstract Slides Video
Presentation thumbnail
The no-cut technique for lead preparation in transvenous lead extraction: a preliminary single centre experience
Doctor M. Baroni (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Tauropace reduces infections in patients with heart failure and reduced ejection fraction after cardiac electronic implantable device implantation.
Doctor D. Faccenda (Lugan, CH)
Abstract Slides Video
Presentation thumbnail
Extraction of novel, small diameter OmniaSecure defibrillation lead from the deep septum in sheep
Mrs M. Upchurch (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Retrospective observational study of tricuspid regurgitation in patients with device implantation (PM, CRT) in LBBP Position
Assistant Professor G. Leventopoulos (Patras, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Device complications and lead extraction

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Real-world evaluation of the PRAETORIAN score in subcutaneous ICD recipients: a multicenter registry
thumbnail
Congress Presentation
The predictive value of impedance for defibrillation success after subcutaneous implantable cardioverter-defibrillator implantation: a reliable indicator?
thumbnail
Congress Presentation
Equal performance of the subcutaneous and transvenous implantable cardioverter defibrillator across all age groups in the PRAETORIAN trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources